Hired in October 2019 to the role of Managing Director and Chief Legal Counsel, Khiron Europe, Katterbach’s promotion to the position of President aligns with the company’s commitment to diversity and inclusion throughout the organization, including at the executive level, the company said in a statement.

“I would like to congratulate Franziska on her appointment, which comes at a very exciting time for our European team. Since joining Khiron, Franziska has been a driving force behind our European operations. Her regulatory expertise, strong leadership skills and exceptional day-to-day management of operations have allowed us to develop a differentiated, asset-light platform. Most recently, the European team launched another new product into the German market while more than tripling shipment volumes, demonstrating strong execution in Europe’s largest market,” said Alvaro Torres, CEO and Director.

Franziska Katterbach herself added: “I am a great believer in Europe’s medical cannabis market and am honored to lead our world-class team as we expand patient access, along with our market presence, in Germany and the UK. On behalf of the Company, I would like to thank Tejinder for his many contributions to our European operations and wish him well in his future endeavors.”

Tejinder Virk left the company to head Akanda, formerly known as Halo Collectives, with operations in Lesotho. His resignation will result in the forfeiture of 2.2 million stock options and 600,000 restricted share units previously awarded.

See also: Khiron Life Sciences CEO Álvaro Torres Discusses The Cannabis Company’s Unique Go-To-Market Strategy & Its Network Of Zerenia Integrative Care Clinics

This represents a new revenue stream for Khiron and positions its European team to execute on its German medical strategy. Leveraging Nimbus Health’s large distribution network and Khiron’s ongoing investments in physician education, the Canadian listed firm with Colombian operations will focus on indications such as anxiety, substance use disorder, and migraines, addressing patient needs and improving access to medical cannabis.

The launch product is Khiron’s 1/14 high-CBD flower, which will focus on indications such as anxiety, substance use disorder, and migraines, addressing patient needs and improving access to medical cannabis.

“Since signing our distribution agreement with Nimbus Health in 2020, the company’s European Sales and Marketing teams have been actively educating doctors and raising awareness for our products. We are excited to launch our portfolio with Khiron 1/14, a product that covers unmet medical need in the German market. As we continue to expand our presence in the UK and Germany, we will leverage our clinical expertise from Colombia to provide the EU market with additional cannabis-based medicinal products,” said Tejinder Virk, President of Khiron Europe.

Franziska Katterbach, Managing Director & Chief Legal Officer for Khiron Europe based in Frankfurt, commented, “I would like to thank our European team for their unwavering perseverance over the past few months; their efforts have allowed us to achieve this significant milestone despite the challenges of the global pandemic and Germany’s strict regulatory environment. With all permits in place and product now available for sale, we look forward to increasing our presence in this growing market with over 60,000 medical cannabis patients and a population of over 82 million people. We are already developing additional cannabis-based medicinal products from our certified strains recently imported from Colombia to improve access and product selection for German patients.”